Human gene
SCN8A sodium channel, voltage gated, type VIII alpha subunit
1 disease group in OMIA reaches this gene, through the animal gene that Ensembl gives as its ortholog. The page shows the chain. It does not say whether an animal is a model of a human disease.
Animal diseases
By each group's best natural-model score, highest first. How the score works.
| OMIA group | Name | Species | Animal gene | Ortholog | The chain reached | Best score |
|---|---|---|---|---|---|---|
| 2194 | Ataxia, spinocerebellar, SCN8A-related | dog | SCN8A | one to one | Drug |
61.0
|
Target evidence
Each Open Targets association between this gene and a human disease that a disease group reached.
| Human disease | Mondo | Score | Evidence |
|---|---|---|---|
| developmental and epileptic encephalopathy, 13 | MONDO:0013801 | 0.84 | 332 |
| seizures, benign familial infantile, 5 | MONDO:0014903 | 0.77 | 113 |
| cognitive impairment with or without cerebellar ataxia | MONDO:0013680 | 0.73 | 150 |
Drugs
Each ChEMBL drug that acts on this gene.
| Drug | How | Latest stage |
|---|---|---|
| Articaine | blocker | Approved |
| Benoxinate | blocker | Approved |
| Carbamazepine | blocker | Approved |
| Cenobamate | inhibitor | Approved |
| Chloroprocaine | blocker | Approved |
| Cocaine | blocker | Approved |
| Disopyramide | blocker | Approved |
| Dronedarone | blocker | Approved |
| Dyclonine | blocker | Approved |
| Encainide | blocker | Approved |
| Eslicarbazepine | blocker | Approved |
| Eslicarbazepine Acetate | blocker | Approved |
| Ethotoin | blocker | Approved |
| Etidocaine | blocker | Approved |
| Fosphenytoin | blocker | Approved |
| Hexylcaine | blocker | Approved |
| Indecainide | blocker | Approved |
| Lacosamide | blocker | Approved |
| Lamotrigine | blocker | Approved |
| Lidocaine | blocker | Approved |
| Mephenytoin | blocker | Approved |
| Mepivacaine | blocker | Approved |
| Mexiletine | blocker | Approved |
| Moricizine | blocker | Approved |
| Orphenadrine | blocker | Approved |
| Oxcarbazepine | blocker | Approved |
| Phenacemide | blocker | Approved |
| Phenazopyridine | blocker | Approved |
| Phenytoin | blocker | Approved |
| Prilocaine | blocker | Approved |
| Primidone | blocker | Approved |
| Procainamide | blocker | Approved |
| Procaine | blocker | Approved |
| Propafenone | blocker | Approved |
| Proparacaine | blocker | Approved |
| Propoxycaine | blocker | Approved |
| Quinidine | blocker | Approved |
| Riluzole | blocker | Approved |
| Ropivacaine | blocker | Approved |
| Rufinamide | blocker | Approved |
| Tetracaine | blocker | Approved |
| Tocainide | blocker | Approved |
| Topiramate | blocker | Approved |
| Zonisamide | blocker | Approved |
| Evenamide | blocker | Phase 3 |
| Ralfinamide | blocker | Phase 3 |
| Nerispirdine | blocker | Phase 2 |
| Zandatrigine | inhibitor | Phase 2 |
| Irampanel | blocker | Phase 1 |
| Nktr-171 | blocker | Investigational new drug |
| Dichlorobenzyl Alcohol | blocker | Unknown |
| Merethoxylline Procaine | blocker | Unknown |
| Quinidine Polygalacturonate | blocker | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.